$OTLC Balance Sheet | Understand Stock

$OTLC

$0.03 -$0.00 (1.91%) Close

$OTLC Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
ASSETS
Current assets:
Cash
Restricted cash
Accounts receivable
Prepaid & other current assets
Prepaid and other current assets
Total current assets
Development equipment, net of accumulated depreciation of $111,958 and $101,810
Intangibles, net of accumulated amortization of $201,180 and $188,339 as of Dec 31, 2022 and 2021
In process R&D
Goodwill, net of impairment
Investment in GMP Bio at fair value
Investment in equity securities
Investment owned
Total assets

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued liabilities
Accounts payable - related party
Accounts payable to related party
Related Party
Total accounts payable to related party

Contingent consideration
Derivative liability on notes
Convertible debt for clinical trial and JV
Convertible and short-term debt, net of costs
Convertible debt and short-term debt - related party, net of costs
Convertible debt and short-term debt, net of costs
Related Party
Nonrelated Party
Total convertible debt and short-term debt, net of costs
Convertible debt, related party, net of costs
Convertible debt 2021, net of costs
Private Placement convertible notes, net of costs
Private Placement convertible notes, related party, net of costs
Payroll Protection Plan loan
Total current liabilities

Convertible long-term debt, net of costs
Convertible long-term debt, net of costs
Related Party
Nonrelated Party
Total convertible long-term debt, net of costs
Total noncurrent liabilities
Deferred income tax liability
Total liabilities
Stockholders’ equity:
Convertible preferred stock, $0.01 par value, 15,000,000 shares authorized; 50,900 and 24,388 issued and outstanding, respectively
Common stock, $0.01 par value; 750,000,000 shares authorized; 457,012,796 and 442,596,856 issued and outstanding, respectively
Additional paid-in capital
Accumulated equity
Total Oncotelic Therapeutics, Inc. stockholders’ equity
Non-controlling interests
Total stockholders’ equity
Total liabilities and stockholders’ equity

Comments